Isomorphic Labs announces Johnson & Johnson research collaboration
Isomorphic Labs →Isomorphic Labs announced a cross-modality, multi-target research collaboration with Johnson & Johnson. The partnership combines Isomorphic’s AI-first approach with Johnson & Johnson’s drug-discovery and development expertise. The company described its foundational design engine as capable of generating candidates across challenging targets and modalities, including small molecules, antibodies, peptides and molecular glues. The collaboration is intended to use these discovery capabilities, including large-molecule and biologics design. The announcement establishes a research relationship, not an equity investment or evidence that a medicine has achieved regulatory approval. No financial consideration is disclosed on the announcement page, and no payment amount or commercial outcome is inferred here.